Chester County News and Community Website
WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) has enrolled the first patient in its Phase 3 clinical trial evaluating IKT-001 for pulmonary arterial hypertension, advancing development of the drug …
Inhibikase Enrolls First Patient in Phase 3 PAH Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix, an investigational treatment aimed …
Medicus Submits Phase 2 Study Design for Teverelix to FDA Read More
WILMINGTON, DE — AstraZeneca reported that its drug combination including IMFINZI and IMJUDO, used with lenvatinib and transarterial chemoembolization, improved progression-free survival in patients with unresectable liver cancer eligible for …
AstraZeneca Trial Shows Improved Outcomes in Liver Cancer Study Read More
PHILADELPHIA, PA — The U.S. Food and Drug Administration recently granted Breakthrough Therapy Designation to plixorafenib, an investigational drug from FORE Biotherapeutics, for the treatment of adults with BRAF V600E-mutated …
FDA Grants Breakthrough Status to Fore Bio Brain Cancer Drug Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) issued a clarification of previously reported Phase 2 trial results for its SkinJect therapy in nodular basal cell carcinoma, the company said.
Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy Read More
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease.
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced the publication of an article detailing the development of its lead drug candidate buntanetap as the company continues clinical trials for …
Annovis Bio Highlights Buntanetap Development in Published Article Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported a confirmed partial response in its ongoing Phase 1 clinical trial evaluating APR-1051, a WEE1 kinase inhibitor, in patients with biomarker-defined …
Aprea Reports Partial Response in APR-1051 Cancer Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it has submitted an optimized Phase 2 clinical trial protocol to the U.S. Food and Drug Administration for teverelix, an investigational …
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) reported 54-week Phase III data showing its experimental drug povorcitinib reduced disease activity in patients with moderate to severe hidradenitis suppurativa, the company announced …
Incyte Drug Shows Reduced COPD-like HS Flares in Phase III Data Read More